Comirnaty Bivalent Vaccine
What is Comirnaty bivalent vaccine?
Comirnaty Original / Omicron BA.4-5 Vaccine (the “Comirnaty bivalent vaccine”) is a vaccine used for preventing COVID-19 caused by SARS-CoV-2. Based on the available clinical data, among subjects who received the Comirnaty bivalent vaccine or the ancestral strain vaccine as booster after completion of primary series, the antibody level against Omicron BA.4-5 and its increment were higher after receiving the Comirnaty bivalent vaccine compared to the ancestral strain vaccine.
Is the Comirnaty bivalent vaccine effective and safe?
Comirnaty bivalent vaccine has been registered as pharmaceutical products in Hong Kong. Comirnaty Bivalent Vaccine has met safety, efficacy, and quality standards, which is supported by sufficient clinical and vaccination data.
Who is recommended to receive the Comirnaty bivalent vaccine?
Comirnaty bivalent vaccine is recommended as a booster shot. Please complete the COVID-19 vaccine primary series before receiving Comirnaty bivalent vaccine. Please refer to Appendix 1 for the common name(s) and dose(s) required for COVID-19 vaccine primary series completion.
For individuals without previous COVID-19 infection, they are advised to receive Comirnaty at least 90 days after completing their COVID-19 vaccine primary series.
For individuals aged 18-49 years with previous COVID-19 infection, they are advised to receive Comirnaty at least 180 days after their recovery.
For individuals aged 50 years or above with previous COVID-19 infection, they are advised to receive Comirnaty at least 90 days after their recovery.
Note: For recovered individuals aged 50 years or above, Comirnaty bivalent vaccine is allowed at least 28 days after the recovery to cater for personal need (e.g., to fulfil a requirement for overseas travel).
Who should not be given the Comirnaty bivalent vaccine?
Please do not receive the Comirnaty bivalent vaccine if you are allergic to the active substance or any other ingredients of this medicine including:
((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) / 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) / 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC) / cholesterol / trometamol / trometamol hydrochloride / sucrose / water for injections
Product Details:
Given as an injection of 0.3mL into a muscle of your upper arm.
Redemption Validity:
This vaccination service will be valid until 31 Aug 2023. Customer must redeem and complete the vaccination within the period.
Vaccine Manufacturers:
Fosun-BioNTech
Designated Vaccination Centre:
New Territories:
Shatin
Booking method:
Please complete your booking registration form through the following URL or QR code after the payment:
Comirnaty bivalent vaccination registration form URL:
Hong Kong citizens registration form: Click here
Non-Hong Kong citizens registration form: Click here
Comirnaty bivalent vaccination registration form QR code:
(For Hong Kong citizens only)
(For non-Hong Kong citizens only)
Warnings and precautions:
Please consult your doctor if:
- You have ever had a severe allergic reaction or breathing problems after any other vaccine injection or after you were given Comirnaty in the past.
- You are feeling nervous about the vaccination process or have ever fainted following any needle injection.
- You have a severe illness or infection with high fever. Vaccination should be delayed for individuals suffering from acute febrile disease.
- You have bleeding problem, you bruise easily or you use a medicine to prevent blood-clots.
- You have a weakened immune system, because of a disease such as HIV infection or a medicine such as a corticosteroid that affects your immune system.
- There is an increased risk of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) after vaccination with Comirnaty. These conditions can develop within just a few days after vaccination and have primarily occurred within 14 days. They have been observed more often after the second vaccination, and more often in younger males. Following vaccination, you should be alert to signs of myocarditis and pericarditis, such as breathlessness, palpitations, and chest pain, and seek immediate medical attention should these occur. Adolescents and young adults should avoid strenuous exercise for one week after Comirnaty vaccination.
- Pregnant and lactating women can receive this vaccine. (A large amount of information from studies suggested that pregnant women vaccinated with Comirnaty during the second and third trimester have not shown negative effects on the pregnancy or the newborn baby.) Whereas individual cases may vary, please consult your doctor before the vaccination during pregnancy.
Recommended for
Individuals aged 18 or above (age as at the date of vaccination)
